Last reviewed · How we verify
BPL-003
At a glance
| Generic name | BPL-003 |
|---|---|
| Sponsor | Beckley Psytech Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression (PHASE2)
- An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder (PHASE2)
- BPL-003 Efficacy and Safety in Treatment Resistant Depression (PHASE2)
- Single Ascending Dose Study With BPL-003 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPL-003 CI brief — competitive landscape report
- BPL-003 updates RSS · CI watch RSS
- Beckley Psytech Limited portfolio CI